Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: A 4-year follow-up study

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 2, 2014, Pages

  Cheng, Yuan Yang ^a,b   Leu, Hsin Bang ^b,c   Chen, Tzeng Ji ^c   Chen, Chen Ling ^a   Kuo, Chia Hua ^d   Lee, Shin Da ^e   Kao, Chung Lan ^b,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF TAIPEI   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

diabetes mellitus; hazard ratio; Metformin; stroke

Indexed keywords

METFORMIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TAIWAN;

DIABETES MELLITUS; HAZARD RATIO; METFORMIN; STROKE;

ADMINISTRATION, ORAL; AGED; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893347537     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2013.09.001     Document Type: Article

References (36)

1. Data provided by Ministry of Health and Welfare, Taiwan. Available at: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f-list-no=312&fod-list-no= 2747. Accessed on September 26, 2013.
2. B.P. Lucke-Wold, R.C. Turner, and A.N. Lucke-Wold et al. Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke Yale J Biol Med 85 2012 523 539
3. M.H. Zou, S.S. Kirkpatrick, and B.J. Davis et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species J Biol Chem 279 2004 43940 43951
4. M.H. Zou, and Y. Wu AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function Clin Exp Pharmacol Physiol 35 2008 535 545
5. J. Li, S.E. Benashski, and V.R. Venna et al. Effects of metformin in experimental stroke Stroke 41 2010 2645 2652
6. M.M. Elgebaly, R. Prakash, and W. Li et al. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling J Cereb Blood Flow Metab 30 2010 1928 1938
7. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
8. S.E. Kahn, S.M. Haffner, and M.A. Heise et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
9. Z.Y. Chen, C.H. Chiang, and C.C. Huang et al. The association of tooth scaling and decreased cardiovascular disease: a nationwide population-based study Am J Med 125 2012 568 575
10. C.H. Chiang, C.C. Huang, and W.L. Chan et al. Association between Mycoplasma pneumonia and increased risk of ischemic stroke: a nationwide study Stroke 42 2011 2940 2943
11. G.K. Panicker, D.R. Karnad, and V. Salvi et al. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs J Assoc Physicians India 60 2012 56 61
12. E. Selvin, S. Bolen, and H.C. Yeh et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Arch Intern Med 168 2008 2070 2080
13. C.L. Roumie, A.M. Hung, and R.A. Greevy et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Ann Intern Med 157 2012 601 610
14. A. Qaseem, L.L. Humphrey, and D.E. Sweet et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 156 2012 218 231
15. Y. Ido, D. Carling, and N. Ruderman Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP activated protein kinase activation Diabetes 51 2002 159 167
16. D. Kukidome, T. Nishikawa, and K. Sonoda et al. Activation of AMP activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells Diabetes 55 2006 120 127
17. N. Ouslimani, J. Peynet, and D. Bonnefont-Rousselot et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells Metabolism 54 2005 829 834
18. B.J. Davis, Z. Xie, and B. Viollet et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase Diabetes 55 2006 496 505
19. V.A. Morrow, F. Foufelle, and J.M. Connell et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells J Biol Chem 278 2003 31629 31639
20. K. Isoda, J.L. Young, and A. Zirlik et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells Arterioscler Thromb Vasc Biol 26 2006 611 617
21. D.G. Harrison, P.J. Marvar, and J.M. Titze Vascular inflammatory cells in hypertension Front Physiol 3 2012 128
22. I. Ikonomidis, C.A. Michalakeas, and J. Parissis et al. Inflammatory markers in coronary artery disease Biofactors 38 2012 320 328
23. G. Siasos, D. Tousoulis, and E. Oikonomou et al. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice Curr Pharm Des 17 2011 4132 4146
24. M.Y. El-Mir, D. Detaille, and G. R-Villanueva et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons J Mol Neurosci 34 2008 77 87
25. I. Ullah, N. Ullah, and M.I. Naseer et al. Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons BMC Neurosci 13 2012 11
26. A. Lee, and J.E. Morley Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes Obes Res 6 1998 47 53
27. J.C. Chan, B. Tomlinson, and J.A. Critchley et al. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients Diabetes Care 16 1993 1035 1038
28. D. Giugliano, N. De Rosa, and G. Di Maro et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women Diabetes Care 16 1993 1387 1390
29. K. Landin, L. Tengborn, and U. Smith Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors J Intern Med 229 1991 181 187
30. D. Giugliano, A. Quatraro, and G. Consoli et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors Eur J Clin Pharmacol 44 1993 107 112
31. M.S. Muntzel, I. Hamidou, and S. Barrett Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats Hypertension 33 1999 1135 1140
32. X.Y. Xing, Y.F. Li, and Z.D. Fu et al. Antihypertensive effect of metformin in essential hypertensive patients with hyperinsulinemia Zhonghua Nei Ke Za Zhi 49 2010 14 18
33. I. Eleftheriadou, P. Grigoropoulou, and N. Katsilambros et al. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism Curr Diabetes Rev 4 2008 340 356
34. P.J. Grant Beneficial effects of metformin on haemostasis and vascular function in man Diabetes Metab 29 2003 6S44 52
35. F.W. Germino Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review Clin Ther 33 2011 1868 1882
36. L.B. Goldstein, C.D. Bushnell, and R.J. Adams et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 517 584